Interim results of Phase 1 trials are showing that INO 4800 is the safest vaccine in the market so far - with much less side effects compare to any other vaccine candidate.
Moreover - initial plan for phase 1 human trials was based on 40 healty volunteers between 18 to 55 years old, however on the late stage trials were expanded to include even lower dosage (think about it would initially planned dosage not produce enough immune response - would you start amending your trials to include even lower dosage). Moreover phase 1 trials were expanded from 40 volunteers to 120 volunteers inclusive volunteers above 65 with no upper age limit.
(sign that there was no any side effects with younger and healthier volunteers).
As such - there are positive reasons behind little delay with peer- review publication of phase 1 results.
Being the first - doesn't mean being the best.
INO will be the winner.